Signature Genomic Laboratories, LLC (Signature) and Agilent
Technologies, Inc. (NYSE: A), today announced they have signed a
long-term supply agreement in which Agilent will supply custom
oligonucleotide microarrays based on the Signature-designed
SignatureChip Oligo SolutionTM (SignatureChipOSTM)
to Signature and its customers.
Terms of the agreement were not disclosed.
The SignatureChipOS is designed for the detection of chromosome
abnormalities in individuals with mental retardation/developmental
delay, autism and congenital anomalies. The 105,000-feature, 60-mer
microarray covers over 150 syndromes, the subtelomeric and
pericentromeric regions, and more than 500 genes in important
developmental pathways.
“We are committed to giving our customers the
best services and technology available, and this agreement reflects this
focus,” said Lisa G. Shaffer, Ph.D., President
and CEO of Signature. “Oligo arrays have
improved dramatically in the past few years and we are delighted there
are now oligos that meet our high standards. This supply agreement also
allows our Genoglyphix®
customers the opportunity to use high quality oligo arrays for research
applications in their laboratories.”
“We’re very pleased
about this agreement, which is the latest example of how the marketplace
is recognizing the value of our highly-flexible, high quality oligo
synthesis capability,” said Yvonne Linney,
Ph.D., Agilent Vice President and General Manager, Genomics.
About Agilent Technologies
Agilent is a leading provider of research microarrays used to analyze
gene expression, microRNA, comparative genomic hybridization and
ChIP-on-chip. More information about Agilent microarrays is available at www.opengenomics.com.
Agilent Technologies Inc. (NYSE: A) is the world’s
premier measurement company and a technology leader in communications,
electronics, life sciences and chemical analysis. The company’s
19,000 employees serve customers in more than 110 countries. Agilent had
net revenue of $5.4 billion in fiscal year 2007. Information about
Agilent is available on the Web at www.agilent.com.
About Signature Genomic Laboratories
Genoglyphix® is the innovative software
created and used by Signature Genomic Laboratories. Information about
Genoglyphix is available at www.genoglyphix.com.
The SignatureChipOS was developed and its performance characteristics
determined by Signature Genomic Laboratories as required by CLIA ’88
regulations. It has not been cleared or approved for specific uses by
the US Food and Drug Administration. Pursuant to the requirements of
CLIA ’88, Signature Genomic Laboratories has
established and verified the test’s accuracy
and precision.
Signature Genomic Laboratories, founded in 2003, was the first
laboratory to provide microarray-based cytogenetic diagnostics with its
proprietary SignatureChip® and is the leader
in providing microarray-based chromosome analysis. Signature’s
worldwide client base includes clinical geneticists, neurologists,
pediatricians, neonatologists, obstetricians, and the research
community. Signature is CAP accredited, CLIA certified, and has clinical
licenses from California, Rhode Island and Florida. Additional
information about Signature Genomic Laboratories is available at www.signaturegenomics.com.
